I am a board-certified medical oncologist who specializes in the care of patients with liver, gallbladder, pancreas, and other gastrointestinal cancers. My primary goal is to provide the best possible treatment and individualized care for patients with these diseases. To realize this goal, I work closely with a multidisciplinary team of surgeons, radiation oncologists, and other medical professionals who specialize in the diagnosis and treatment of gastrointestinal malignancies.
I engage in clinical research aimed at finding new effective therapies for these cancers, particularly primary liver tumors. My research initiatives include the development of innovative ways to use a patient’s own immune system to fight cancer and new strategies to block specific cellular pathways critical for cancer growth. My research has been supported by the American Society of Clinical Oncology.
- Clinical Expertise: Gastrointestinal Malignancies; Hepatobiliary Cancers; Pancreatic Cancer
- Languages Spoken: English
- Education: MD, Albert Einstein College of Medicine
- Residencies: Internal Medicine - New York Presbyterian Hospital
- Fellowships: Oncology/Hematology - Memorial Sloan Kettering Cancer Center
- Board Certifications: Internal Medicine; Medical Oncology
Research is integral to our mission at Memorial Sloan Kettering, and clinical trials help us discover better forms of patient care and treatment. For you, this could mean access to a new therapy or therapy combination. Click to see a list of the trials I’m currently leading.
Clinical Trials Led by James J. Harding
- A Phase I Study of ADI-PEG 20 plus FOLFOX in Patients with Advanced Digestive Cancers
- A Phase I Study of CB-839 in Patients with Advanced Solid Tumors
- A Phase I Study of PF-06671008 Immunotherapy in Patients with Advanced Solid Tumors
- A Phase I/II Study of Enzalutamide with and without Sorafenib in Patients with Advanced Liver Cancer
- A Phase Ib Study of Ramucirumab plus LY2875358 in Patients with Advanced Cancer
- A Phase II Study of LY2157299 (Galunisertib) plus Ramucirumab in Patients with Liver Cancer
- A Phase III Study of Nivolumab Immunotherapy versus Sorafenib as Initial Treatment for Advanced Liver Cancer
Clinical Trials Co-Investigated by James J. Harding
- A Phase I Study of AZD5363 in Patients with Solid Tumors Who Have AKT1 and PIK3CA Mutations
- A Phase II Study of ENMD-2076 in Patients with Fibrolamellar Liver Cancer
- A Phase II Study of Entrectinib in Patients with Locally Advanced or Metastatic Solid Tumors Containing Gene Rearrangements in NTRK1/2/3, ROS1, or ALK
- A Phase II Study of MEDI4736 and Tremelimumab, as Monotherapy or in Combination, in Unresectable Hepatocellular Carcinoma
- A Phase III Study of Cabozantinib versus Placebo in Patients with Liver Cancer Who Received Previous Therapy with Sorafenib
Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.Learn more